Stock A217730 KANGSTEM BIOTECH CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Kangstem Biotech Co., Ltd.

Equities

A217730

KR7217730001

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
2,635 KRW -1.50% Intraday chart for Kangstem Biotech Co., Ltd. -0.94% +10.02%
Apr. 25 An undisclosed buyer agreed to acquire a 24.27% stake in Croen Inc. from Kangstem Biotech Co., Ltd. for KRW 2.8 billion CI
2023 Kangstem Biotech Co., Ltd.(KOSDAQ:A217730) dropped from S&P Global BMI Index CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 453,984 169,714 196,458 124,057 109,830 133,971
Enterprise Value (EV) 1 432,721 152,424 176,683 81,515 86,521 110,220
P/E ratio -29.3 x -6.89 x -9.55 x -4.27 x -5.43 x -4.43 x
Yield - - - - - -
Capitalization / Revenue 49.5 x 28.3 x 21.5 x 10 x 6.74 x 10.5 x
EV / Revenue 47.2 x 25.4 x 19.3 x 6.57 x 5.31 x 8.68 x
EV / EBITDA -41.4 x -7.24 x -11.2 x -4.32 x -5.18 x -5.84 x
EV / FCF -37.3 x -6.03 x -16.5 x -5.33 x -6.36 x -11 x
FCF Yield -2.68% -16.6% -6.07% -18.7% -15.7% -9.06%
Price to Book 9.52 x 2.46 x 3.83 x 1.82 x 2.23 x 2.79 x
Nbr of stocks (in thousands) 20,825 20,849 24,837 37,938 37,938 55,938
Reference price 2 21,800 8,140 7,910 3,270 2,895 2,395
Announcement Date 3/13/19 3/17/20 3/17/21 3/16/22 3/15/23 3/13/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 9,165 6,005 9,138 12,405 16,301 12,704
EBITDA 1 -10,457 -21,056 -15,732 -18,862 -16,688 -18,862
EBIT 1 -11,694 -23,154 -18,725 -22,736 -20,558 -22,777
Operating Margin -127.59% -385.6% -204.92% -183.28% -126.12% -179.29%
Earnings before Tax (EBT) 1 -14,063 -26,302 -19,756 -21,811 -20,215 -23,137
Net income 1 -13,648 -24,635 -18,471 -21,348 -20,236 -21,949
Net margin -148.91% -410.26% -202.14% -172.1% -124.14% -172.77%
EPS 2 -744.7 -1,182 -828.4 -766.6 -533.4 -540.6
Free Cash Flow 1 -11,590 -25,257 -10,731 -15,281 -13,595 -9,991
FCF margin -126.45% -420.62% -117.43% -123.19% -83.4% -78.64%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/13/19 3/17/20 3/17/21 3/16/22 3/15/23 3/13/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 21,262 17,291 19,775 42,542 23,309 23,751
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -11,590 -25,257 -10,731 -15,281 -13,595 -9,991
ROE (net income / shareholders' equity) -40.3% -45.4% -33.7% -36.4% -32.5% -45.2%
ROA (Net income/ Total Assets) -12.3% -15.5% -11.9% -15.3% -14% -17.6%
Assets 1 111,211 159,030 154,791 139,460 144,687 124,768
Book Value Per Share 2 2,290 3,314 2,067 1,793 1,300 858.0
Cash Flow per Share 2 155.0 368.0 401.0 199.0 123.0 105.0
Capex 1 1,608 15,342 3,038 4,631 712 1,392
Capex / Sales 17.55% 255.51% 33.25% 37.33% 4.37% 10.96%
Announcement Date 3/13/19 3/17/20 3/17/21 3/16/22 3/15/23 3/13/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
KANGSTEM BIOTECH CO., LTD. Stock Kangstem Biotech Co., Ltd.
+10.02% 107M
MODERNA, INC. Stock Moderna, Inc.
+26.28% 42.68B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.99% 42.4B
LONZA GROUP AG Stock Lonza Group AG
+45.32% 40.04B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.36% 24.94B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.47% 18.96B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.58% 12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.75% 11.95B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-2.02% 11.55B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. A217730 Stock
  4. Financials Kangstem Biotech Co., Ltd.